Physician profile
Meredith Brady
NPI 1306563754
$2,413.77
in general payments reported to CMS, 2019-2025
18 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,371 · 2024: $710 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $653.70 | 2023-2025 | |
| Abbott Laboratories | $328.82 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Tandem Diabetes Care, INC. | $257.86 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $195.11 | 2023-2024 | Afrezza |
| Kyowa Kirin, INC. | $187.58 | 2023-2024 | Crysvita |
| Ascendis Pharma Endocrinology INC | $104.16 | 2023-2025 | Skytrofa |
| Alexion Pharmaceuticals, INC. | $103.00 | 2023-2024 | Strensiq |
| Tolmar, INC. | $102.10 | 2023-2024 | |
| Azurity Pharmaceuticals, INC. | $96.66 | 2023-2024 | Triptodur, Triptodur |
| Novo Nordisk INC | $92.53 | 2023-2025 | Sogroya, Norditropin |
| Lilly USA, LLC | $65.16 | 2023 | Baqsimi |
| Biomarin Pharmaceutical INC. | $57.42 | 2023-2024 | Voxzogo 1.2mg |
| Sanofi-Aventis U.S. LLC | $55.98 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $37.16 | 2023 | Recorlev, Gvoke Hypopen |
| Soleno Therapeutics, INC. | $28.55 | 2025 | Vykat Xr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $21.93 | 2023 | Dexcom G6 Transmitter |
| Cequr Corporation | $13.20 | 2023 | Cequr Simplicity |
| Regeneron Healthcare Solutions, INC. | $12.85 | 2023 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.